Eli Lilly and Company $LLY Shares Sold by Arvest Investments Inc.

Arvest Investments Inc. reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 73.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 967 shares of the company’s stock after selling 2,702 shares during the period. Arvest Investments Inc.’s holdings in Eli Lilly and Company were worth $1,039,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Orca Investment Management LLC lifted its position in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Orca Investment Management LLC now owns 1,887 shares of the company’s stock worth $2,028,000 after purchasing an additional 11 shares in the last quarter. Investment Research & Advisory Group Inc. lifted its position in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Investment Research & Advisory Group Inc. now owns 7,311 shares of the company’s stock worth $7,874,000 after purchasing an additional 31 shares in the last quarter. Red Door Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Red Door Wealth Management LLC now owns 3,314 shares of the company’s stock worth $3,562,000 after purchasing an additional 11 shares in the last quarter. Coign Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.3% during the fourth quarter. Coign Capital Advisors LLC now owns 866 shares of the company’s stock worth $931,000 after purchasing an additional 11 shares in the last quarter. Finally, Raab & Moskowitz Asset Management LLC increased its stake in shares of Eli Lilly and Company by 1.4% in the fourth quarter. Raab & Moskowitz Asset Management LLC now owns 2,529 shares of the company’s stock worth $2,718,000 after buying an additional 35 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $930.08 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market cap of $878.76 billion, a price-to-earnings ratio of 40.53, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a fifty day moving average of $988.75 and a 200-day moving average of $973.25.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on LLY shares. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Guggenheim dropped their price target on shares of Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Argus lifted their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,222.22.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high‑value product opportunity that could add billions to sales and validate Lilly’s oral GLP‑1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP‑1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price‑target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next‑generation Tau aggregation inhibitors with IND‑enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near‑term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower‑priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP‑1 price war and side‑effect/competition concerns that have driven short‑term profit‑taking and tempered the stock’s post‑approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.